ADRB2 and respiratory tract infectious disorder: Given that the prolonged use of β2AR agonists is associated with sustained or severe disease activity due to COPD, asthma, or other respiratory infections, it is notable that the long-term use of β2AR agonists was associated with a significantly decreased incidence of all vascular complications as compared with the non-users.